Trodelvy Offers Benefits for Hormone Receptor-Positive Breast Cancer

Trodelvy Offers Benefits for Hormone Receptor-Positive Breast Cancer

Dr. Hope Rugo discusses the latest results from the TROPiCS-02 trial showing Trodelvy improves overall survival compared to chemotherapy in metastatic, hormone receptor-positive, HER2-negative breast cancer.
Sep 22, 2022
/_next/static/media/art.743baba8.png
00:00
Download
00:00

At the European Society for Medical Oncology Congress 2022, Dr. Rugo presented results from the TROPiCS-02 trial, which was looking to see if the targeted therapy Trodelvy (chemical name: sacituzumab govitecan-hziy) could offer more benefits for people diagnosed with previously treated, metastatic, hormone receptor-positive, HER2-negative breast cancer than chemotherapy. Currently, Trodelvy is approved to treat previously-treated, metastatic triple-negative breast cancer.

Listen to the episode to hear Dr. Rugo explain:

  • the type of medicine Trodelvy is and how it works

  • the results showing people diagnosed with previously treated, metastatic, hormone receptor-positive, HER2-negative breast cancer lived longer when they received Trodelvy compared to chemotherapy

  • how the results from TROPiCS-02 fit into current treatment options

About the guest
 
hope-rugo
Hope S. Rugo, MD

Affiliations: University of California San Francisco Helen Diller Family
Comprehensive Cancer Center, Translational Breast Cancer Research Consortium, Bioasis

Areas of specialization: medical oncology, hematology, breast cancer

Dr. Hope Rugo is a medical oncologist specializing in breast cancer research and treatment. A professor of medicine at the University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, Dr. Rugo is the director of the Breast Oncology Clinical Trials
Program.

— Last updated on September 28, 2022, 2:42 PM

 
Lilly

This podcast episode is made possible by Lilly.

 
 
Support Breastcancer.org to produce more content like this

Your donation goes directly to what you read, hear, and see on Breastcancer.org.

Donate